bpc-157 clinical trials human dosing Just Cleared a Major Regulatory Hurdle If you've been following the peptide world, you've probably heard the buzz about BPC-157. Here's what actually happened: ✓ An FDA advisory committee voted to The Complete BPC-157 Dosage Guide:

Since neurogenic mydriasis (e.g., caused by head injury, tumor) responds (pupillary constriction) to local instillation of a parasympathomimetic, failure of the pupillary sphincter to constrict within 30 minutes after instillation of several drops of a 0.5 or 1% ophthalmic solution of pilocarpine, in the absence of local ocular injury (traumatic iridoplegia) or increased intraocular pressure (angle-closure glaucoma), usually indicates chemically induced (e.g., scopolamine) blockade of the sphincter

However, the lack of clinical trials means that there could potentially be serious BPC-157 side effects in humans, which remain unknown

Mechanisms of resistance to antibody-drug conjugates

Keep out of reach of children and unauthorized individuals

EU approval typically follows FDA approval by 36 months